Biotech Values

[BTH]

That's pretty incredible actually.
I was always under the impression that Roche was the powerhouse in oncology - I guess I never paid any attention to their pipeline (unless it implicated my direct holdings as in the case of CRIS and GDC-449 aka Vismodegib).

Vismodegib should be on the slate, next up.